SCHEMBL1007863

SCHEMBL1007863

O=C(CCCn1nc(C(F)(F)F)c2c1CCCC2)NCc1cccs1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.57
HTT P42858 1/20 0.57
USP2 O75604 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
MAPT P10636 6/20 0.47
TP53 P04637 2/20 0.47
POLB P06746 1/20 0.46
LMNA P02545 6/20 0.46
POLQ O75417 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
GRIA2 P42262 1/20 0.46
HPGD P15428 1/20 0.45
GAA P10253 2/20 0.45
TSHR P16473 2/20 0.45
HSD17B10 Q99714 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1007931 0.88 SMN1; SMN2 (0.62) SMN1; SMN2MAPTTP53POLBLMNA
SCHEMBL1008071 0.86 SMN1; SMN2 (0.62) ALDH1A1SMN1; SMN2MAPTTP53POLB
SCHEMBL1889998 0.83 SMN1; SMN2 (0.46) ALDH1A1HTTSMN1; SMN2MAPTTP53
SCHEMBL1006091 0.82 ALDH1A1 (0.61) ALDH1A1HTTSMN1; SMN2MAPTTP53
SCHEMBL1008186 0.81 ALDH1A1 (0.54) ALDH1A1HTTSMN1; SMN2MAPTTP53
SCHEMBL1894160 0.80 RAB9A (0.49) ALDH1A1HTTSMN1; SMN2MAPTTP53
SCHEMBL1005696 0.79 TDP1 (0.61) SMN1; SMN2MAPTTP53POLBLMNA
SCHEMBL4657057 0.79 GRIA2 (0.64) POLBLMNAMEN1KMT2ACYP1A2
SCHEMBL1008414 0.79 ALDH1A1 (0.56) ALDH1A1HTTSMN1; SMN2MAPTTP53
SCHEMBL1007171 0.78 ALDH1A1 (0.67) ALDH1A1HTTMAPTTP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
US-20110118236-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 US disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 EP disclosed
WO-2009119088-A1 HETEROCYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118236-A1 HETEROCYCLIC COMPOUND GRIN1, GRM1, GRIK1 ALDH1A1 614/4885HTT 3487/4885USP2 4641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.